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Continuing danger of glucose point-of-
care test devices in the neonatal setting
To the Editor: We write to alert medical and nursing staff to a 
continuing problem in the neonatal setting, which has featured 
in the correspondence pages of the SAMJ on at least two prior 
occasions.[1,2] Recently, in KwaZulu-Natal province, at least 4 infants 
with galactosaemia have been affected by the phenomenon of 
galactose interfering with glucose meters and producing high 
readings, resulting in the misdiagnosis of hyperglycaemia. 
Unlike some developed countries, there is no routine newborn 
screening programme for galactosaemia in South Africa (SA), with 
the result that the correct diagnosis is made only after significant 
illness has developed. A recent study in SA estimated the incidence 
in African patients to be approximately 1/14 400;[3] accordingly, it is 
likely that many cases are undetected. 
Often, blood sampling for important laboratory tests is technically 
extremely difficult in the sick neonate and point-of-care test (POCT) 
devices are used, which only require a few μl of whole blood. The 
most ubiquitous of these is probably the handheld glucometer (Roche 
Accuchek is the instrument typically supplied to public hospitals). 
Under optimal conditions of careful usage and quality control, such 
POCT devices are extremely useful for clinical management. However, 
many use the glucose dehydrogenase pyrroloquinoline quinone 
(GDH-PQQ)-based glucose measuring system. While physiological 
levels of plasma galactose (usually <0.5 mmol/l) do not affect the 
meter’s readings, galactose, at the clinically relevant concentrations 
found in galactosaemia, is able to cause positive interference. The 
result is the misdiagnosis of hyperglycaemia. Levels of galactose >0.83 
mmol/l will cause overestimation of glucose levels. 
In the cases referred to above, neonates were judged to have 
‘hyperglycaemia’ and, based on this finding, were treated with insulin, 
with disastrous consequences. Galactosaemia, in fact, often results 
in hypoglycaemia caused by hepatic accumulation of galactose-1-
phosphate, which inhibits enzymes of glycogenolysis; including glucose-6-
phosphatase, glucose-6-phosphate dehydrogenase, phosphoglucomutase 
and glycogen phosphorylase. The inadvertent administration of insulin 
to such affected neonates, in whom blood glucose is already dangerously 
low, obviously has the effect of lowering glucose levels further.
It is of critical importance that high readings from POCT 
glucometers that suggest hyperglycaemia in neonates are confirmed 
by a formal measurement of glucose in the laboratory before 
treatment is instituted. The clinician is well advised to check the urine 
for glucose and reducing substances, to see if this concurs with the 
presumptive diagnosis of hyperglycaemia. 
Clinicians should exercise caution when using POCT instruments, as 
they are intended to supplement, rather than replace laboratory testing. 
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